<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745808</url>
  </required_header>
  <id_info>
    <org_study_id>CAS-XDA-DEF/IGDB</org_study_id>
    <nct_id>NCT02745808</nct_id>
  </id_info>
  <brief_title>Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes</brief_title>
  <official_title>Injectable Collagen Scaffold™ Combined With Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) for the Improvement of Erectile Function in Men With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent of this clinical study is to answer the questions: 1) is the proposed treatment
      feasible; 2) is treatment effective in improving the disease pathology of patients with
      diagnosed diabetic erectile dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability assessed by Adverse Events</measure>
    <time_frame>1 month after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in IIEF-5 (International Index of Erectile Function)</measure>
    <time_frame>1,3,6,9 and 12 months</time_frame>
    <description>The subjects must fill in the questionnaire of IIEF-5 every visit to evaluate erectile function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in penile colour Doppler ultrasonography</measure>
    <time_frame>1,3,6,9 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HUC-MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracavernous injection of 15 million HUC-MSCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injectable Collagen Scaffold + HUC-MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HUC-MSCs</intervention_name>
    <description>The subjects will receive intracavernous injection of HUCMSC.</description>
    <arm_group_label>HUC-MSCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injectable Collagen Scaffold + HUC-MSCs</intervention_name>
    <description>The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.</description>
    <arm_group_label>Injectable Collagen Scaffold + HUC-MSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 1 or 2 diabetes,blood glucose controlled well, no effective with oral PDE-5i

          2. Have a consistent partner who is willing to engage in sexual activity more than twice
             per month during the study

          3. Males, age 20-65 years

          4. IIEF-5 score is under 16

          5. Penile arterial insufficiency or venous leakage (doppler): peak systolic velocity（PSV）
             &lt;25 cm/sec, or peak systolic velocity（PSV）&gt;25 cm/sec, end-diastolic velocity（EDV）&gt;
             5cm/sec, resistance index（RI）&lt;0.75

          6. HbA1c is between 6.5%-10%

          7. Physical examination with no abnormalities

          8. Willing to consent to participate in the study follow-up

          9. Willing to limit alcohol intake eliminate use of recreational drugs for sexual
             encounters.

        Exclusion Criteria:

          1. Severe cardiovascular disease (angina, arrhythmia, cardiac failure, stroke), kidney
             failure, respiratory failure; history of malignancy

          2. Positive for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C
             Virus (HCV) syphilis test

          3. Testosterone level is less than 200ng/dL

          4. Serum AST/ALT &gt;3*upper limit of normal or creatinine &gt;1.5*upper limit of normal

          5. HbA1c exhibit greater than 10%

          6. In the investigators judgment, with clinical significance of penis abnormalities, or
             has received penile prosthesis implantation surgery

          7. Patients partner is trying to conceive during the trial period

          8. Exposure to any investigational drug or procedure within 1 month prior to study entry
             or enrolled in a concurrent study that may confound results of this study

          9. Unwilling and/or not able to give written informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianwu Dai, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhifeng Xiao, Ph.D</last_name>
    <phone>86-10-82614420</phone>
    <email>zfxiao@genetics.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sufang Han, Ph.D</last_name>
    <phone>86-10-82614420</phone>
    <email>sufanghan22@genetics.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yutian Dai, M.D.</last_name>
      <phone>86-25-83106666</phone>
      <phone_ext>70502</phone_ext>
      <email>13913957628@163.com</email>
    </contact>
    <contact_backup>
      <last_name>LeiLei Zhu, M.D.</last_name>
      <phone>86-25-83106666</phone>
      <phone_ext>70502</phone_ext>
      <email>zhuleilei68n@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Jianwu Dai</investigator_full_name>
    <investigator_title>Principal Investigator of Regenerative Medicine Laboratory, Institute of Genetics and Developmental Biology, CAS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

